title: [Effects of icotinib hydrochloride on the proliferation and apoptosis of human lung cancer cell lines].
abstract: OBJECTIVE
  To explore the effects of icotinib on the proliferation and apoptosis of various lung cancer cell lines.
  
  
  METHODS
  Human lung cancer cell lines HCC827, H1650, H1975, A549 and human epidermal cancer cell line A431 were treated in vitro with icotinib or gefitinib at a concentration gradient of 0 - 40 µmol/L. Their proliferation effects were analyzed by the thiazolyl blue (MTT) assay and the apoptotic effects detected by flow cytometer. The downstream signaling proteins were detected by Western blot.
  
  
  RESULTS
  The median inhibitory concentrations (IC(50)) of icotinib for A431 and HCC827 cell lines were (0.04 ± 0.02) and (0.15 ± 0.06) µmol/L respectively. No significant differences existed between the inhibitions of gefitinib and icotinib on A431, HCC827, H1650, H1975 and A549 cell lines (all P > 0.05). Compared with H1650, H1975 and A549 cell lines, icotinib significantly inhibited A431 (P = 0.009, 0.005 and 0.000) and HCC827 (P = 0.001, 0.001 and 0.000) cell lines. And it lowered the expressions of p-AKT, p-ERK and survivin protein expression through the inhibited activity of p-EGFR protein.
  
  
  CONCLUSIONS
  Icotinib can arrest the proliferation of lung adenocarcinoma cells with EGFR mutation or over-expression by inhibiting the signal pathways of AKT-ERK and survivin.
authors.affiliation: Department of Medical Oncology, Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Han
authors.forename: Shuai
authors.initials: S
authors.lastname: Wang
authors.forename: Jian-fei
authors.initials: JF
authors.lastname: Wang
authors.forename: Yuan-kai
authors.initials: YK
authors.lastname: Shi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D043844:Crown Ethers / Q000494:pharmacology*; D066246:ErbB Receptors / Q000378:metabolism; D000077156:Gefitinib; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology*; D015398:Signal Transduction; D000077022:Survivin
chemical_list: D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D043844:Crown Ethers; D051034:Inhibitor of Apoptosis Proteins; D011799:Quinazolines; D000077022:Survivin; C531470:icotinib; D066246:ErbB Receptors; D051057:Proto-Oncogene Proteins c-akt; D000077156:Gefitinib